← Back to Calendar
Live Company Data
NMS
Updated
32m ago
· Data: FMP
Current Price
$62.97
+45.80%
+$19.78 today
Day: $61.67 – $63.67
52-Week Range
Current price is at 81% of 52-week range
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Indication
Non-obstructive hypertrophic cardiomyopathy (nHCM)
Key Notes
ACACIA-HCM Phase 3 topline readout expected Q2 2026 (company guidance confirmed multiple times, including Q4 2025 earnings Feb 24, 2026 and Citi Life Sciences Conference March 2026). 420-patient randomized, double-blind, placebo-controlled study evaluating health-related quality of life (KCCQ-23) in nHCM at 36 weeks. BMS Camzyos (mavacamten) recently failed in nHCM — making ACACIA a potential first targeted therapy for nHCM. Positive readout would double aficamten's addressable HCM market and support an sNDA for nHCM label expansion. Major binary event for CYTK.
⚠️ Not Investment Advice: This information is provided for educational purposes only.
PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period,
issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on
historical base rates and do not account for drug-specific factors. Always consult a financial advisor
before making investment decisions.
Discussion
Share your analysis, research, or questions about this catalyst. No account required.